Deconstructing Meta-Analyses From ESC 2025

Host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP, discusses the validity of meta-analyses and highlights 2 specific publicatins from the European Society of Cardiology (ESC) 2025 Congress with Bill Baker, PharmD, FCCP, FACC, FAHA, a member of the department of pharmacy practice at UConn School of Pharmacy.

Beavers and Baker discuss the methodology and utility of meta-analyses, highlighting benefits and pitfalls of the strategy. They showcase 2 meta-analyses: an individual participant data analysis of the VICTORIA and VICTOR trials regarding use of vericiguat (Verquvo; Merck), and an analysis of randomized controlled trials investigating the use of β blockers after myocardial infarction with mildly reduced ejection fraction. The experts break down the studies and the implications for patients and pharmacists alike.

Show Notes:

• Pooled Analysis From VICTOR and VICTORIA Trials
• β Blocker After Myocardial Infarction Meta Analysis